Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Breast Cancer
Interventions: Radiation, No Radiation; Radiation · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 35 Years and older · Female only
Enrollment: 2,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 451
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more

Conditions: Sjögren's Syndrome
Interventions: LY3090106, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Baltimore, Maryland • Albuquerque, New Mexico • Concord, North Carolina + 1 more

Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions: Enzelkitug, Atezolizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more

Conditions: Breast Cancer, Ovarian Neoplasm, Pain
Interventions: Omega-3 fatty acid, Placebo, Paclitaxel; Dietary Supplement · Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Albuquerque, New Mexico

Conditions: HIV Infections, Lipodystrophy
Interventions: Leptin, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 14 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Ovarian Carcinoma, Pancreatic Exocrine Neoplasm, Stage IVB Prostate Cancer American Joint Committee on Cancer v8, Triple-Negative Breast Carcinoma
Interventions: Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview, Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Rochester, New York

Conditions: Hereditary Angioedema
Interventions: Sebetralstat; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 2 Years to 11 Years
U.S. locations: 6
States / cities: San Diego, California • Evansville, Indiana • Wheaton, Maryland + 3 more

Conditions: Hidradenitis Suppurativa
Interventions: CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 8
States / cities: Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more

Conditions: Systemic Lupus Erythematosus, SLE, Lupus
Interventions: Vitamin D3, Vitamin D3 placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 5 more

Conditions: Atopic Dermatitis, Type 1 Hypersensitivity
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 0 Days to 14 Days
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Metastatic Breast Cancer
Interventions: Ribociclib, Palbociclib, Abemaciclib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 4,320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Atopic Dermatitis
Interventions: Skin tape strips; Other
Lead sponsor: National Jewish Health; Other
Eligibility: 4 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Wound Heal, Peripheral Artery Disease, Ulcer, Leg, Ulcer Foot, Diabetic Foot Ulcer, Arterial Insufficiency
Interventions: Noxsano Bandage (Healthy Volunteers), Noxsano Bandage (Wound Care); Device
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years to 79 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more

Conditions: Pancreatic Neoplasm, Peutz-Jeghers Syndrome
Interventions: Biopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma
Interventions: Talimogene laherparepvec, GM-CSF; Biological
Lead sponsor: BioVex Limited; Industry
Eligibility: 18 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 57
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: Lung Diseases, Interstitial
Interventions: Belimumab, Placebo; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 17
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 11 more

Conditions: Staphylococcal Skin Infection
Interventions: Telavancin, Vancomycin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Breast Cancer
Interventions: Exercise Training, Chemo only; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Plaque Psoriasis
Interventions: Elimune Capsules; Dietary Supplement
Lead sponsor: Elorac, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Chicago, Illinois • Lake Forest, Illinois • Fair Lawn, New Jersey + 1 more

Conditions: Breast Cancer, Joint Pain
Interventions: Chondroitin, Glucosamine; Drug
Lead sponsor: Dawn L. Hershman; Other
Eligibility: 21 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Treatment with Halobetasol propionate 0.05% topical spray; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 13
States / cities: North Hollywood, California • Pasadena, California • Hialeah, Florida + 6 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Tecogalan sodium; Drug
Lead sponsor: Daiichi Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Placebo, Lovaza, Dietary energy restriction; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 30 Years to 55 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Search by objective public record fields.

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

Therapeutic Approaches to HAART-Induced Lipodystrophy

Access to Genetic Testing in Underserved Patients With Cancer

Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Vitamin D3 in Systemic Lupus Erythematosus

Allergic Disease Onset Prevention Study

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Skin Tape Transcriptome Methods in Children

Safety and Efficacy of the Noxsano Wound Care Bandage

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Cancer of the Pancreas Screening Study (CAPS 3)

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.

Evaluate the Effect of Elimune Capsules

Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

A Study of Tecogalan Sodium

Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue